Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Trevi Therapeutics
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kilogram per meter square (kg/m2) at Screening.
Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the principal investigator (PI) or designee.
You may not be if
Positive results for coronavirus infection (COVID-19) at Screening or check-in (Day -1).
History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
Positive urine drug or alcohol results at Screening or check in (Day -1).
Smoker who has smoked or used nicotine containing products within the last 3 months prior to the first dose and throughout the study, confirmed by a negative cotinine test at Screening and check-in (Day -1).
History or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.
Hemoglobin, absolute neutrophil count, or platelet levels outside of the reference range at Screening.
History of prolonged QT syndrome or a corrected QT (QTc) interval.
Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
Participation in another clinical study within 5 half-lives or 30 days, whichever is longer, of the Baseline visit.
Clareo Health | A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
